AstraZeneca subsidiary to sell its Bangalore site, to hunt for external manufacturer 

As­traZeneca’s In­dia sub­sidiary is sell­ing its on­ly man­u­fac­tur­ing site in Ban­ga­lore as part of an on­go­ing strate­gic re­view of its man­u­fac­tur­ing and sup­ply net­work, ac­cord­ing to a Thurs­day reg­u­la­to­ry fil­ing.

As­traZeneca Phar­ma In­dia is sell­ing the fa­cil­i­ty in a “ful­ly op­er­a­tional man­ner.” It is look­ing for a buy­er who will al­so man­u­fac­ture — on con­tract — its drug prod­ucts cur­rent­ly made or pack­aged at the same Ban­ga­lore site, the fil­ing states.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

The XBI comedown after JPM

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian

Read More »